Outcomes of Broader Genomic Profiling in Metastatic Colorectal Cancer: a Portuguese Cohort Study
Authors:
Preprint
- 16 December 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Colorectal cancer (CRC) is the third most diagnosed cancer globally and the second leading cause of cancer-related deaths. Despite advancements, metastatic CRC (mCRC) has a five-year survival rate below 20%. Next-generation sequencing (NGS) can identify rare actionable mutations and assess tumour mutational burden (TMB), but its clinical utility in mCRC is debated due to limited survival improvement and cost-effectiveness concerns. Methods: This retrospective study included mCRC patients (≥18 years) treated at a single oncology center who underwent NGS during treatment planning. Tumour samples were analyzed using either a 52-gene Oncomine™ Focus Assay or a 500+ gene Oncomine™ Comprehensive Assay Plus. Variants were classified by clinical significance (ESMO ESCAT) and potential benefit (ESMO-MCBS and OncoKBTM). Kaplan-Meier and Cox regression analyses evaluated survival outcomes, with significance at p<0.005. Results: Eighty-six metastatic colorectal cancer (mCRC) patients were analysed, all MMR proficient. Most cases (73.3%) underwent sequencing at metastatic diagnosis, using primary tumour samples (74.4%) and a focused NGS assay (75.6%). A total of 206 somatic variants were detected in 86.0% of patients, 31.1% of which were classified as clinically significant, predominantly KRAS mutations (76.6%), with G12D and G12V variants as the most frequent. Median overall survival (OS) was 39.5 months, with no single mutation predictive of OS. Among 33.7% RAS/BRAF wild-type patients, 65.5% received anti-EGFR therapies. Eleven patients (12.8%) had other actionable variants ESCAT level I-II, including four identified as TMB-high, four KRAS G12C, two BRAF V600E and one HER2 amplification. Four received OncoKbTM level 1-2 and ESMO-MCBS score 4, leading to disease control in three cases. Conclusions: NGS enables the detection of rare variants, supports personalized treatments, and expands therapeutic options. As new drugs emerge and genomic data integration improves, NGS is poised to enhance real-world mCRC management.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Comparing baseline VAF in circulating tumor DNA and tumor tissues predicting prognosis of patients with colorectal cancer liver metastases after curative resectionClinics and Research in Hepatology and Gastroenterology, 2024
- Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2024
- Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directionsCancer Treatment Reviews, 2024
- Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative dataeClinicalMedicine, 2024
- Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre networkMolecular Oncology, 2023
- The prognostic role of p53 mutations in metastatic colorectal cancer: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2023
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- Biomarker concordance between primary colorectal cancer and its metastasesEBioMedicine, 2019
- Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patientsInternational Journal of Clinical Oncology, 2019